{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Class:
PROTEIN
Class:
PROTEIN
Lusupultide is a genetically engineered surfactant preparation containing recombinant surfactant protein C (rSP-C) embedded in a phospholipid matrix. It reduces surface tension and keeps the alveoli open, thus ensuring a stable surface for oxygen passage. Lusupultide had got orphan designations from EMA for the treatment of acute respiratory distress syndrome and aspiration pneumonitis requiring intubation and mechanical ventilation. Lusupultide development has been discontinued.
Status:
Investigational
Source:
NCT01552681: Phase 2 Interventional Terminated Primary Sjögren's Syndrome
(2012)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02452554: Phase 2 Interventional Completed Pleuropulmonary Blastoma
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:dalnicastobart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:rafivirumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT04639180: Phase 3 Interventional Active, not recruiting Hepatocellular Carcinoma (HCC)
(2021)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:pegevongitide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02336698: Phase 3 Interventional Completed Osteoarthritis
(2015)
Source URL:
Class:
PROTEIN
